Tranylcypromine
Parnate, Tranylcypromine (tranylcypromine) is a small molecule pharmaceutical. Tranylcypromine was first approved as Parnate on 1985-08-16. It is used to treat depressive disorder and post-traumatic stress disorders in the USA. The pharmaceutical is active against amine oxidase [flavin-containing] B and amine oxidase [flavin-containing] A. In addition, it is known to target lysine-specific histone demethylase 1A and prostacyclin synthase.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| mental disorders | D001523 |
Trade Name
FDA
EMA
Parnate, Tranylcypromine
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Tranylcypromine sulfate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| PARNATE | ADVANZ PHARMA | N-012342 RX | 1985-08-16 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| parnate | New Drug Application | 2025-07-02 |
| tranylcypromine | ANDA | 2024-12-20 |
| tranylcypromine sulfate | NDA authorized generic | 2025-07-25 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| post-traumatic stress disorders | EFO_0001358 | D013313 | F43.1 |
| depressive disorder | EFO_1002014 | D003866 | F32.A |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
36 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Depression | D003863 | — | F33.9 | 1 | — | 1 | 5 | 2 | 9 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | 2 | 1 | — | 4 | 2 | 8 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | 2 | 1 | — | 4 | 2 | 8 |
| Hemorrhage | D006470 | MP_0001914 | R58 | — | — | 2 | 3 | 2 | 7 |
| Treatment-resistant depressive disorder | D061218 | — | — | — | — | — | 4 | 2 | 6 |
| Knee osteoarthritis | D020370 | EFO_0004616 | M17 | — | — | — | 4 | — | 4 |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | — | — | 2 | 1 | 3 |
| Postoperative hemorrhage | D019106 | — | — | — | — | — | 1 | 1 | 2 |
| Atrophy | D001284 | — | — | — | — | — | 1 | — | 1 |
| Mood disorders | D019964 | EFO_0004247 | F30-F39 | — | — | — | 1 | — | 1 |
Show 5 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Dementia | D003704 | EFO_0003862 | F03 | — | — | 1 | — | — | 1 |
| Psychophysiologic disorders | D011602 | — | F45.9 | — | — | 1 | — | — | 1 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | 1 | — | — | 1 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | — | 1 | — | — | 1 |
| Somatoform disorders | D013001 | — | F45 | — | — | 1 | — | — | 1 |
| Cerebral hemorrhage | D002543 | — | — | — | — | 1 | — | — | 1 |
| Hemorrhagic stroke | D000083302 | — | — | — | — | 1 | — | — | 1 |
| Gastrointestinal hemorrhage | D006471 | — | K92.2 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myelodysplastic syndromes | D009190 | — | D46 | 2 | 1 | — | — | — | 2 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 2 | 1 | — | — | — | 2 |
| Recurrence | D012008 | — | — | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypotension | D007022 | EFO_0005251 | I95 | 1 | — | — | — | — | 1 |
| Pure autonomic failure | D054970 | — | — | 1 | — | — | — | — | 1 |
| Orthostatic hypotension | D007024 | — | I95.1 | 1 | — | — | — | — | 1 |
| Leukemia | D007938 | — | C95 | 1 | — | — | — | — | 1 |
| Melanosis | D008548 | EFO_0003963 | L81.1 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Rotator cuff injuries | D000070636 | — | M75.1 | — | — | — | — | 1 | 1 |
| Congenital heart defects | D006330 | — | Q24.9 | — | — | — | — | 1 | 1 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | — | — | 1 | 1 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | — | 1 | 1 |
| Postoperative complications | D011183 | — | — | — | — | — | — | 1 | 1 |
| Surgical blood loss | D016063 | — | — | — | — | — | — | 1 | 1 |
| Leiomyoma | D007889 | — | D25 | — | — | — | — | 1 | 1 |
| Myofibroma | D047708 | — | — | — | — | — | — | 1 | 1 |
| Obstetric labor complications | D007744 | — | — | — | — | — | — | 1 | 1 |
| Postpartum hemorrhage | D006473 | — | O72 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Tranylcypromine |
| INN | tranylcypromine |
| Description | (1R,2S)-tranylcypromine is a 2-phenylcyclopropan-1-amine that is the (1R,2S)-enantiomer of tranylcypromine. It is a conjugate base of a (1R,2S)-tranylcypromine(1+). It is an enantiomer of a (1S,2R)-tranylcypromine. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | N[C@@H]1C[C@H]1c1ccccc1.N[C@H]1C[C@@H]1c1ccccc1 |
Identifiers
| PDB | — |
| CAS-ID | 155-09-9 |
| RxCUI | 10734 |
| ChEMBL ID | CHEMBL3989843 |
| ChEBI ID | — |
| PubChem CID | 19493 |
| DrugBank | DB00752 |
| UNII ID | 3E3V44J4Z9 (ChemIDplus, GSRS) |
Target
Agency Approved
MAOB
MAOB
MAOA
MAOA
Alternate
KDM1A
KDM1A
PTGIS
PTGIS
Organism
Homo sapiens
Gene name
KDM1A
Gene synonyms
AOF2, KDM1, KIAA0601, LSD1
NCBI Gene ID
Protein name
lysine-specific histone demethylase 1A
Protein synonyms
[histone H3]-dimethyl-L-lysine(4) FAD-dependent demethylase 1A, amine oxidase (flavin containing) domain 2, BRAF35-HDAC complex protein BHC110, FAD-binding protein BRAF35-HDAC complex, 110 kDa subunit, Flavin-containing amine oxidase domain-containing protein 2, lysine (K)-specific demethylase 1A, lysine-specific histone demethylase 1
Uniprot ID
Mouse ortholog
Kdm1a (99982)
lysine-specific histone demethylase 1A (Q8VEA1)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Tranylcypromine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,605 documents
View more details
Safety
Black-box Warning
Black-box warning for: Parnate, Tranylcypromine, Tranylcypromine sulfate
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
585 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use